Should You Forget Eli Lilly and Buy This Magnificent Biotech Stock Instead?

Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has helped its earnings and its stock soar in recent times. It consists of the company's weight loss drugs: Mounjaro, approved for type 2 diabetes but also prescribed off-label for weight control, and Zepbound, specifically approved for the weight control indication.These drugs, both dual GIP/GLP-1 receptor agonists, work by acting on hormones involved in the digestion process -- and as a result they help control blood sugar levels and appetite. Lilly and its big pharma rival Novo Nordisk today dominate the weight loss drug market, but competition may be on the horizon.In fact, one up-and-coming player is attracting a lot of attention these days, thanks to its fantastic clinical trial results. And its first weight loss candidate may soon launch phase 3 trials, the last stage of development prior to regulatory review. I'm talking about Viking Therapeutics (NASDAQ: VKTX).Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool